Combined effects of S-1, a new form of oral tegafur, plus modulators on ovarian cancer in nude rats.
We evaluated the efficacy of S-1 as a new oral antitumor agent in ovarian cancer-bearing nude rats. This drug consists of tegafur, 5-chloro-2,4-dihydroxypyridine, and oxonic acid in a molar ratio of 1:0.4:1.S-1 was given alone or in combination with cisplatin. When administered alone at a daily dose of 20 mg/ kg, S-1 produced a significant inhibition of tumor growth [inhibition rate (IR) 89%] in the treated versus the control animals (p < 0.05). The effects of S-1 resembled those of cisplatin-treated groups. The consecutive daily administration of S-1, 20 mg/kg, combined with cisplatin, 1 mg/kg, markedly inhibited cell growth (IR 99%), a significant difference relative to cisplatin alone (p < 0.05). The daily administration of S-1 combined with low-dose cisplatin induced tumor regression with a low toxicity.
Suzuki
M
M
Department of Obstetrics and Gynecology, Jichi Medical School, Tochigi, Japan.
Sekiguchi
I
I
Sato
I
I
Shirasaka
T
T
D000284:Administration, Oral; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use* / Q000633:toxicity; D001835:Body Weight / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002945:Cisplatin / Q000627:therapeutic use / Q000633:toxicity; D005260:Female; D005472:Fluorouracil / Q000097:blood; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D009368:Neoplasm Transplantation; D010051:Ovarian Neoplasms / Q000097:blood / Q000188:drug therapy*; D010094:Oxonic Acid / Q000627:therapeutic use / Q000633:toxicity; D011725:Pyridines / Q000627:therapeutic use / Q000633:toxicity; D051381:Rats; D011923:Rats, Nude; D005641:Tegafur / Q000627:therapeutic use / Q000633:toxicity; D014183:Transplantation, Heterologous
D011725:Pyridines; D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin; D005472:Fluorouracil; C104201:gimeracil